STOK – stoke therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome [Yahoo! Finance]
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Form 8-K Stoke Therapeutics, Inc. For: Jan 11
Form 4 Stoke Therapeutics, Inc. For: Dec 31 Filed by: LEVIN ARTHUR A
Form 8-K Stoke Therapeutics, Inc. For: Dec 05
Form 4 Stoke Therapeutics, Inc. For: Dec 08 Filed by: Kaye Edward M. MD
Form 4 Stoke Therapeutics, Inc. For: Dec 08 Filed by: Allan Jonathan
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.